Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
Antabio SAS, the biopharmaceutical company focused on developing a
broad pipeline of antibacterial treatments against life threatening WHO critical priority pathogens, announces that it has been awarded up to $4.4 million in a second tranche funding from CARB-X, the global nonprofit partnership dedicated to tackling the global rising threat of drug-resistant bacteria. The funding is to support the development of Antabio’s novel small molecule candidate for the treatment of Pseudomonas
aeruginosa infections in Cystic Fibrosis (CF) patients.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
